[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood; 2000 Sep 15;96(6):2037-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
  • Most patients with multiple myeloma (MM) present with symptoms, have evidence of generalized disease, and require chemotherapy promptly to reduce the malignant clone.
  • Some patients present with a local symptom from a single plasmacytoma but no myeloma elsewhere.
  • In patients with MM without symptoms, the diagnosis is made on the basis of screening laboratory tests.
  • In patients with either solitary plasmacytoma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression.
  • [MeSH-major] Bone Neoplasms. Multiple Myeloma. Plasmacytoma


2. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R: Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer; 2002 Mar 1;94(5):1532-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
  • BACKGROUND: Prognostic factors for solitary plasmacytoma of bone (SPB), whether measured before or after radiotherapy (RT), have not been established.
  • The authors analyzed multiple factors for myeloma-free survival (MFS) and cause-specific survival (CSS) in SPB patients treated with RT alone.
  • Patient ages ranged from 29-77 years (median, 54 years), and 75% of patients had a myeloma (M) protein in the blood and/or urine.
  • Radiotherapy to the solitary lesion was given to a total dose of 30-70 Gy (median, 46 Gy).
  • The authors analyzed the impact of multiple factors on MFS and CSS, including resolution v. persistence of M protein after RT, secretory v. nonsecretory disease at diagnosis, presence v. absence of an associated soft tissue mass on computed tomography or MRI scan, magnitude of serum M protein elevation at diagnosis, age, spinal v. nonspinal location, Karnofsky performance status, total RT dose, and tumor size.
  • On multivariate analysis, persistence of M protein more than one year after RT was the only independent adverse prognostic factor for MFS (P = 0.005) and CSS (P = 0.04).
  • Most patients with M protein that persisted for more than one year after RT were diagnosed with multiple myeloma within 2.2 years of treatment.
  • CONCLUSIONS: Patients with M protein that persists for more than one year after RT should be monitored frequently and considered for standard chemotherapy followed by intensive consolidation therapy when they either develop symptoms or show an increasing M protein level.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / radiotherapy. Multiple Myeloma / pathology. Myeloma Proteins / analysis. Plasmacytoma / pathology. Plasmacytoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920511.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  •  go-up   go-down


3. Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacémi Y, Bolla M, Oner FD, Landmann C, Castelain B, Ozsahin M, Rare Cancer Network: Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer; 2006;6:118
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
  • BACKGROUND: Solitary plasmacytoma (SP) of the bone is a rare plasma-cell neoplasm.
  • There are no conclusive data in the literature on the optimal radiation therapy (RT) dose in SP.
  • METHODS: Data from 206 patients with bone SP without evidence of multiple myeloma (MM) were collected.
  • Histopathological diagnosis was obtained for all patients.
  • The majority (n = 169) of the patients received RT alone; 32 chemotherapy and RT, and 5 surgery.
  • RESULTS: Five-year overall survival, disease-free survival (DFS), and local control was 70%, 46%, and 88%; respectively.
  • Median time to MM development was 21 months (2-135) with a 5-year probability of 51%.
  • There was no dose-response relationship for doses 30 Gy or higher, even for larger tumors.
  • Further investigation should focus on adjuvant chemotherapy and/or novel therapeutic agents.
  • [MeSH-major] Bone Neoplasms / mortality. Plasmacytoma / mortality
  • [MeSH-minor] Actuarial Analysis. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Dexamethasone / administration & dosage. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Doxorubicin / administration & dosage. Europe / epidemiology. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Middle Aged. Multiple Myeloma / epidemiology. North America / epidemiology. Prednisone / administration & dosage. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Spinal Neoplasms / drug therapy. Spinal Neoplasms / mortality. Spinal Neoplasms / pathology. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1990 Apr;17(4):293-303 [2343147.001]
  • [Cites] Eur J Haematol. 1990 Feb;44(2):132-5 [2318296.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):128-33 [7819027.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):687-91 [8664190.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Aug;17(7):1349-54 [8871723.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):329-33 [8892456.001]
  • [Cites] Br J Cancer. 1997;75(6):921-7 [9062417.001]
  • [Cites] Br J Radiol. 1997 May;70(833):511-6 [9227234.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1063-7 [9719116.001]
  • [Cites] Eur J Haematol. 1999 Apr;62(4):271-7 [10227461.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Eur J Haematol. 2005 Nov;75(5):370-5 [16191085.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):210-7 [16229966.001]
  • [Cites] Hematol Oncol. 1996 Sep;14(3):111-7 [9119355.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2037-44 [10979944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):113-20 [11316553.001]
  • [Cites] Br J Haematol. 2002 Apr;117(1):133-5 [11918544.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1532-7 [11920511.001]
  • [Cites] Curr Treat Options Oncol. 2002 Jun;3(3):255-9 [12057071.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1715-7 [12393501.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Oct;18(5):841-5 [14629832.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):717-26 [15009059.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Nov;6(11):1497-501 [6780494.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):845-51 [7248911.001]
  • [Cites] J Clin Oncol. 1983 Apr;1(4):255-62 [6668499.001]
  • [Cites] J Clin Oncol. 1987 Nov;5(11):1811-5 [3681369.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):43-8 [2912957.001]
  • [Cites] Radiother Oncol. 1999 Sep;52(3):245-9 [10580871.001]
  • [Cites] Oncology (Williston Park). 2000 Jan;14(1):101-8, 111; discussion 111-2, 115 [10680152.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1311-5 [8315427.001]
  • (PMID = 16677383.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone; VAD I protocol
  • [Other-IDs] NLM/ PMC1479355
  •  go-up   go-down


Advertisement
4. Mendenhall WM, Mendenhall CM, Mendenhall NP: Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol; 2003 Nov-Dec;24(6):395-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone and soft tissues.
  • PURPOSE: To define the optimal treatment and outcomes for patients with solitary plasmacytoma of bone and soft tissue.
  • RESULTS: Solitary plasmacytomas are uncommon and account for less than 5% of plasma cell neoplasms.
  • Solitary plasmacytomas of bone (SPB) usually occur in the vertebra and skull and are more common than extramedullary plasmacytomas (EMP) that almost always arise in the head and neck and may spread to regional lymph nodes.
  • The optimal treatment is moderate-dose radiotherapy (40-50 Gy) and occasionally surgery.
  • Adjuvant chemotherapy does not improve survival.
  • Patients with EMP have a relatively low risk of progressing to multiple myeloma and have improved survival compared with those who present with SPB.
  • CONCLUSION: Solitary plasmacytoma is an uncommon neoplasm that often arises in the head and neck.
  • Optimal treatment is moderate-dose radiotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Plasmacytoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Male. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14608572.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


5. Seoane J, Aguirre-Urizar JM, Esparza-Gómez G, Suárez-Cunqueiro M, Campos-Trapero J, Pomareda M: The spectrum of plasma cell neoplasia in oral pathology. Med Oral; 2003 Aug-Oct;8(4):269-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma cell tumors are lymphoid neoplastic proliferations of B cells that may be classified as multiple myeloma (MM), solitary bone plasmacytoma (SBP) and extramedullary plasmacytoma (PEM).
  • These types of neoplasia are typically found in adults and may occur as disseminated tumors of the bone marrow or in some cases as solitary bone or extramedullary tumors.
  • Oral manifestations in the form of oral and maxillofacial lesions are often the first sign of the disease.
  • Treatment of these neoplastic tumors varies depending on the type of proliferation and may involve surgery, radiotherapy and chemotherapy, alone or combined.
  • [MeSH-major] Mouth Neoplasms / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Humans. Multiple Myeloma / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12937388.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 121
  •  go-up   go-down


6. Pinto LS, Campagnoli EB, Leon JE, Lopes MA, Jorge J: Maxillary lesion presenting as a first sign of multiple myeloma: case report. Med Oral Patol Oral Cir Bucal; 2007 Sep;12(5):E344-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maxillary lesion presenting as a first sign of multiple myeloma: case report.
  • This denomination encloses multiple myeloma (MM), solitary bone plasmacytoma and extramedullary plasmacytoma.
  • MM consists of a clonal proliferation of plasma cells based in the bone marrow, with various degrees of differentiation.
  • The disease is more frequently in men and the average age at diagnosis is about 60 years.
  • The diagnosis is established by blood and urine exams and medullary biopsy.
  • Patients may present renal failure, bone pain, fatigue, recurrent infections and nervous system dysfunction.
  • Oral manifestations may be the first sign of MM, highlighting the importance of the dentist in the early diagnosis of the disease.
  • Treatment involves mainly irradiation and chemotherapy and the prognosis is generally poor.
  • This paper reports a case of a 65 years old black female who had a complaint of a painful mass in the maxilla that prompted a MM diagnosis.
  • [MeSH-major] Maxillary Neoplasms / diagnosis. Multiple Myeloma / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767095.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Khaliq W, Uzoaru I, Konchanin RP, Sapiente RA, Egner JR: Solitary extramedullary plasmacytoma of the bladder: a case report and literature. Oncology (Williston Park); 2010 Aug;24(9):832-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary extramedullary plasmacytoma of the bladder: a case report and literature.
  • Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma.
  • Less than 5% of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue.
  • Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder.
  • A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder.
  • The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles.
  • SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive.
  • The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP.
  • The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma.
  • Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Plasmacytoma. Radiotherapy. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Biopsy. Cystoscopy. Dexamethasone / administration & dosage. Humans. Male. Radiation Tolerance. Remission Induction. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives. Treatment Failure. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):836 [20923038.001]
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):838 [20923039.001]
  • (PMID = 20923037.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


8. Mellor PJ, Polton GA, Brearley M, Haugland S, Smith KC, Scase TJ, McNeil PE, Holloway A, Archer J, Powell RM, Villiers EJ, Herrtage ME, Argyle DJ, Day MJ: Solitary plasmacytoma of bone in two successfully treated cats. J Feline Med Surg; 2007 Feb;9(1):72-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone in two successfully treated cats.
  • This is the first report of feline solitary plasmacytoma of bone.
  • Clinical signs resolved completely and 4 years after diagnosis the cat remains well and has no electrophoretically detectable paraproteinaemia.
  • A biopsy of sacral bone demonstrated neoplastic plasma cell infiltration.
  • The cat improved clinically with induction chemotherapy (melphalan and methylprednisolone).
  • The same chemotherapeutics were continued at maintenance doses for 4.3 years, at which time there was recurrence of neurological deficits and a palpable sacral mass.
  • Eighteen months into vincristine therapy, there was recurrence of clinical signs and the cat was euthanased, more than 6 years after the initial diagnosis.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / therapy. Plasmacytoma / veterinary. Spinal Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Combined Modality Therapy. Female. Follow-Up Studies. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887373.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


9. Ota K, Tsuda T, Katayama N, Sakaguchi R, Hara I, Hayashi H, Okamoto Y: A therapeutic strategy for isolated plasmacytoma of bone. J Int Med Res; 2001 Jul-Aug;29(4):366-73
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A therapeutic strategy for isolated plasmacytoma of bone.
  • Two cases of solitary plasmacytoma of bone (SPB) were diagnosed.
  • Magnetic resonance imaging showed the osteolytic lesion in the 12th thoracic bone in the first patient and around the 2nd, 3rd and 4th lumbar bones in the second patient.
  • Both patients were first treated with irradiation around the involved bone and then with a course of chemotherapy.
  • In the first patient the tumour region of the bone was surgically removed and replaced with a ceramic spacer.
  • The symptoms of both patients were ameliorated, and the patients remained in good condition for around 3 years without conversion to multiple myeloma.
  • In view of the overall effectiveness of treatments for SPB, our therapeutic strategy deserves careful evaluation.
  • [MeSH-major] Bone Neoplasms / therapy. Plasmacytoma / therapy
  • [MeSH-minor] Adult. Bone Marrow / pathology. Combined Modality Therapy. Female. Humans. Immunoglobulins / blood. Lumbar Vertebrae. Male. Middle Aged. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11675911.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


10. Gaur S, Oo TH, Aish LS, Mansoor S: Gastric relapse of solitary bone plasmacytoma. Am J Clin Oncol; 2005 Jun;28(3):325-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric relapse of solitary bone plasmacytoma.
  • This case report describes a patient with solitary bone plasmacytoma who had a gastric relapse of his tumor.
  • Skeletal surveys, magnetic resonance imaging of the spine, and bone marrow examination done at the time of relapse failed to show any other site of disease.
  • Positron emission tomography finally clarified the true extent of the tumor.
  • [MeSH-major] Plasmacytoma / secondary. Spinal Neoplasms / pathology. Stomach Neoplasms / secondary. Thoracic Vertebrae / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Combined Modality Therapy. Dexamethasone / administration & dosage. Fractures, Spontaneous / etiology. Gastrectomy. Humans. Immunoglobulin A / blood. Magnetic Resonance Imaging. Male. Neoplasm Proteins / blood. Spinal Fractures / etiology. Thalidomide / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923810.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin A; 0 / Neoplasm Proteins; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


11. Dimopoulos MA, Hamilos G: Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol; 2002 Jun;3(3):255-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary bone plasmacytoma and extramedullary plasmacytoma.
  • Solitary bone and extramedullary plasmacytomas are rare plasma cell proliferative disorders.
  • Their diagnosis is based on histologic confirmation of monoclonal plasma cell infiltration of a single disease site and on the exclusion of systemic myeloma.
  • For both entities, the treatment of choice is localized radiotherapy.
  • There is no role for systemic chemotherapy in the management of these disorders.
  • Approximately 30% of patients with solitary bone plasmacytoma (SBP) remain disease-free for several years; some of these patients may be cured.
  • The prognosis of patients with solitary extramedullary plasmacytoma (SEP) appears to be better than for patients with SBP because approximately 70% of patients with SEP remain disease-free at 10 years.
  • With more sensitive staging procedures, the diagnosis of SBP and SEP may become less common, but the number of patients with prolonged stability and cure may increase.
  • [MeSH-major] Bone Neoplasms / therapy. Plasmacytoma / therapy
  • [MeSH-minor] Disease-Free Survival. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Sep 15;96(6):2037-44 [10979944.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):687-91 [8664190.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1532-7 [11920511.001]
  • [Cites] Hematol Oncol. 1992 May-Aug;10(3-4):207-11 [1398516.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1249-57 [10626148.001]
  • [Cites] Haematologica. 2000 Jan;85(1):47-51 [10629591.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Dec;119(6):614-8 [9852535.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1063-7 [9719116.001]
  • [Cites] Radiother Oncol. 1999 Sep;52(3):245-9 [10580871.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):587-90 [1548521.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1311-5 [8315427.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):113-20 [11316553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):43-8 [2912957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):329-33 [8892456.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1513-7 [1540888.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 May;108(5):495-500 [10335713.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):128-33 [7819027.001]
  • (PMID = 12057071.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


12. Yan TQ, Guo W, Tang XD, Tang S: [Clinical study of solitary bone plasmacytoma]. Zhonghua Wai Ke Za Zhi; 2003 Oct;41(10):749-52
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of solitary bone plasmacytoma].
  • OBJECTIVE: To study the clinical characteristics and the prognosis of solitary bone plasmacytoma (SBP).
  • The pathologic diagnose was plasmacytoma and then they underwent further laboratory examination, urine Bence-Jone protein is positive in 3 patients, serous IgG value was higher than normal in 2 patients, abnormal M protein was found in electrophoresis in 2 patients.
  • RESULTS: Four patients were excluded, whose follow-up were lessen than ten months, the other six patients's average follow-up is 28.2 months (from 18 to 48 months), one patient who developed multiple myeloma (MM) six months postoperatively received chemotherapy using M2 protocol and died 21 months after operation.
  • The other five patients had disease-free survive and remain solitary bone lesion after the treatment of surgery and radiology.
  • CONCLUSION: Compared with MM, SBP patients are younger, the therapeutic results and prognosis are better.
  • The main prognostic factors include age, the size of lesion, the axial bone lesion, persistence of myeloma protein after radiotherapy, early diagnosis and treatment, and so on.
  • [MeSH-major] Bone Neoplasms / surgery. Plasmacytoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14766047.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Matsumura S, Kishino M, Ishida T, Furukawa S: Radiographic findings for solitary plasmacytoma of the bone in the anterior wall of the maxillary sinus: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 May;89(5):651-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiographic findings for solitary plasmacytoma of the bone in the anterior wall of the maxillary sinus: A case report.
  • Radiographic findings for a solitary plasmacytoma of the anterior wall of the maxillary sinus are reported.
  • The diagnostic evaluation for this disease is discussed through use of plain images, computed tomography, and magnetic resonance imaging.
  • The treatment selected was radiation therapy combined with chemotherapy.
  • Computed tomography and magnetic resonance imaging revealed bone destruction, though this was not apparent on plain images.
  • [MeSH-major] Maxillary Sinus Neoplasms / radiography. Plasmacytoma / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Cranial Irradiation. Cyclophosphamide / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10807727.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


14. Pratibha CB, Sreenivas V, Babu MK, Rout P, Nayar RC: Plasmacytoma of larynx--a case report. J Voice; 2009 Nov;23(6):735-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoma of larynx--a case report.
  • Plasma cell myeloma, the most common plasma cell neoplasm, is characterized by the presence of multiple lesions in the bone marrow.
  • A single isolated lesion may occur either in bone (solitary plasmacytoma of bone) or in soft tissue (extramedullary plasmacytoma).
  • Most cases of extramedullary plasmacytoma occur in the head and neck region.
  • The diagnosis is established by histopathology and immunohistochemistry.
  • A detailed evaluation for lesions at other sites is recommended as extramedullary plasmacytoma treated by radiation therapy has better survival rates than plasma cell myeloma, which is treated by chemotherapy.
  • A case of plasmacytoma of the larynx is presented highlighting clinical and histological features with a review of literature.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Laryngoscopy. Larynx / pathology. Male. Middle Aged. Treatment Outcome. Vocal Cords / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619786.001).
  • [ISSN] 1873-4588
  • [Journal-full-title] Journal of voice : official journal of the Voice Foundation
  • [ISO-abbreviation] J Voice
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


15. Owotade F, Ugboko V, Ajike S, Salawu L, Amusa Y, Omole M: Head and neck manifestations of myeloma in Nigerians. Int J Oral Maxillofac Surg; 2005 Oct;34(7):761-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck manifestations of myeloma in Nigerians.
  • A study on the clinicopathologic features of myeloma as it manifests in the head and neck region was conducted over a 15-year period.
  • A total of six patients were seen and they constituted 20% of all myeloma cases.
  • Definitive diagnosis was extramedullary myelomatosis in three patients, multiple myeloma in two patients while one patient had solitary plasmacytoma of bone.
  • Chemotherapy alone was the treatment modality in two patients, one had surgery combined with chemotherapy and one patient had only supportive therapy.
  • Two patients did not receive treatment, as they requested for discharge against medical advice.
  • This study confirms the rarity of myeloma in the head and neck region and where it occurs; it is most likely multiple myeloma or extramedullary myelomatosis.
  • In this part of the world, mortality rate is aggravated by late presentation and inability to afford chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Multiple Myeloma / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Nigeria. Plasmacytoma / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979285.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


16. Dagan R, Morris CG, Kirwan J, Mendenhall WM: Solitary plasmacytoma. Am J Clin Oncol; 2009 Dec;32(6):612-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma.
  • PURPOSE: To analyze the outcomes of patients treated for solitary plasmacytoma with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Thirty-two patients with solitary plasmacytoma of bone (SPB; 22 patients) and extramedullary plasmacytoma (EMP; 10 patients) were treated between 1963 and 2006.
  • The median RT dose was around 42.7 Gy (range, 15-54 Gy) over a median of 25 fractions (range, 1-32 fractions).
  • No patient received adjuvant chemotherapy.
  • All 4 patients who developed a local recurrence had SPBs > or = 5 cm.
  • The 10-year multiple myeloma-free survival rates were: SPB, 30%; EMP, 90%; and overall, 50%.
  • Progression to multiple myeloma occurred at a median of 25.1 months after RT.
  • Patients with SPB are more likely to progress to multiple myeloma, which adversely affects their survival compared with those with EMP.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Plasmacytoma / radiotherapy
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Multiple Myeloma / pathology. Multiple Myeloma / radiotherapy. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593082.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Majumdar S, Raghavan U, Jones NS: Solitary plasmacytoma and extramedullary plasmacytoma of the paranasal sinuses and soft palate. J Laryngol Otol; 2002 Nov;116(11):962-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma and extramedullary plasmacytoma of the paranasal sinuses and soft palate.
  • Solitary plasmacytoma of the paranasal sinuses are uncommon neoplasms of B lymphocyte origin.
  • They can be solitary plasmacytomas of the bone (SPB), an extramedullary plasmacytoma or a local manifestation of multiple myeloma.
  • Conversion to multiple myeloma happens more frequently in SPB.
  • Radiotherapy is the common modality of treatment with, or without, adjuvant chemotherapy.
  • Extramedullary plasmacytoma carries a better prognosis than a solitary plasmacytoma of the bone.
  • We report four cases of solitary plasmacytoma of the bone and an extramedullary plasmacytoma of the paranasal sinuses and soft palate.
  • [MeSH-major] Palatal Neoplasms / pathology. Palate, Soft / pathology. Paranasal Sinus Neoplasms / pathology. Plasmacytoma / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12487681.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Singh AD, Chacko AG, Chacko G, Rajshekhar V: Plasma cell tumors of the skull. Surg Neurol; 2005 Nov;64(5):434-8; discussion 438-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Plasma cell tumors are rare neoplasms, which include extramedullary plasmacytoma, solitary plasmacytoma of the bone, and multiple myeloma.
  • Although indistinguishable histopathologically, these entities need to be differentiated as treatment and prognosis vary.
  • The clinico-diagnostic investigations, treatment, and subsequent follow-up of the patients were obtained.
  • In 2 cases, the histopathology was reported as plasmacytoma and further investigations revealed systemic involvement, indicative of multiple myeloma.
  • In 1 patient, the biopsy was reported as multiple myeloma.
  • The above 3 patients underwent radiation, followed by chemotherapy, and there was improvement in their neurologic status at subsequent follow-up.
  • Another patient with a scalp swelling and symptoms of systemic involvement underwent investigations to detect multiple myeloma and, hence, was not subjected to an invasive procedure for histopathologic diagnosis.
  • Chemotherapy was initiated but was discontinued because of social reasons.
  • The last patient in our series died in the immediate postoperative period and although her histopathology was reported as plasmacytoma, she could not be evaluated for systemic involvement.
  • CONCLUSION: The treatment options are different for the systemic form of disease and the localized disease; hence, it is imperative that a rigorous search for systemic involvement is conducted in a case of solitary or extramedullary plasmacytoma.
  • [MeSH-major] Plasmacytoma / pathology. Plasmacytoma / surgery. Skull Neoplasms / pathology. Skull Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253694.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Engelsma RJ, De Bree R, Janssen JJ, Scheeren RA: Plasmacytoma of the mastoid bone: solitary and systemic. J Laryngol Otol; 2000 May;114(5):378-80
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoma of the mastoid bone: solitary and systemic.
  • Two patients are described with a plasma cell tumour in the mastoid bone.
  • In one patient it concerned a solitary plasmacytoma of the bone and in the other a focus in the mastoid of a recently diagnosed multiple myeloma.
  • Computed tomography (CT) and magnetic resonance image (MRI) scanning showed a non-specific space-occupying lesion in the mastoid.
  • The diagnosis was made on immunohistological examination, that showed diffuse sheets of monoclonal plasma cells in a clear matrix.
  • When a plasmacytoma lesion is found multiple myeloma should always be excluded.
  • Treatment in case of solitary plasmacytoma of the mastoid bone consists of radiotherapy.
  • In case of localization in the mastoid of multiple myeloma the treatment consists of palliative chemotherapy.
  • [MeSH-major] Bone Neoplasms / diagnosis. Multiple Myeloma / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging / methods. Mastoid. Middle Aged. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10912271.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


20. Roever AC, Rickes S, Flath B, Possinger K: [Ptosis and ophthalmoplegia as predominant signs of multiple myeloma]. Dtsch Med Wochenschr; 2004 Feb 27;129(9):434-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ptosis and ophthalmoplegia as predominant signs of multiple myeloma].
  • HISTORY AND ADMISSION FINDINGS: A 59-year-old woman was diagnosed as having solitary bone plasmacytoma of the sternum which was resected.
  • DIAGNOSIS, TREATMENT AND COURSE: The biopsy taken from the mass at the sphenoid sinus demonstrated plasmacytoma.
  • The diagnosis of multiple myeloma was based on the histological evidence of plasmacytoma and the occurrence of multiple lytic bone lesions although no infiltration of bone marrow and none of the specific laboratory findings were present.
  • The patient underwent local radiotherapy with 30 Gy followed by systemic chemotherapy.
  • The symptoms regressed completely under this therapy.
  • Knowledge of the histological entity is essential for the correct diagnosis and the appropriate therapy because rare tumors like multiple myeloma may also cause such syndromes.
  • [MeSH-major] Blepharoptosis / etiology. Multiple Myeloma / diagnosis. Ophthalmoplegia / etiology. Skull Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Paranasal Sinus Neoplasms / complications. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / therapy. Plasmacytoma / diagnosis. Plasmacytoma / pathology. Plasmacytoma / surgery. Radiotherapy, Adjuvant. Sphenoid Sinus / pathology. Sternum / pathology. Sternum / surgery. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Tolosa-Hunt Syndrome / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Ptosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14970915.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Kadokura M, Tanio N, Nonaka M, Yamamoto S, Kataoka D, Kushima M, Kimura S, Nakamaki T, Sato I, Takaba T: A surgical case of solitary plasmacytoma of rib origin with biclonal gammopathy. Jpn J Clin Oncol; 2000 Apr;30(4):191-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A surgical case of solitary plasmacytoma of rib origin with biclonal gammopathy.
  • Localized solitary plasmacytoma of the bone (SPB) is a rare disease and is characterized by only one or two isolated bone lesions with no evidence of disease dissemination.
  • The bone marrow biopsy findings revealed no evidence of myeloma and bone scanning revealed only abnormal accumulation in the left seventh rib.
  • Immunoelectrophoresis revealed mild biclonal gammopathy of Bence-Jones protein of both the kappa and lambda light-chain types.
  • Under a diagnosis of solitary bone plasmacytoma, preoperative radiation therapy with doses of 40 Gy for the tumor was performed.
  • Adjuvant chemotherapy using melphalan and prednisolone was performed.
  • He is doing well without evidence of tumor recurrence 2 years following his initial diagnosis.
  • [MeSH-major] Bence Jones Protein / analysis. Hypergammaglobulinemia / etiology. Immunoglobulin kappa-Chains / analysis. Immunoglobulin lambda-Chains / analysis. Muscle Proteins. Plasmacytoma / complications. Ribs / pathology. Thoracic Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Connectin. Humans. Male. Myeloma Proteins / urine. Plasma Cells / pathology. Radiography, Interventional. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10830989.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Connectin; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Muscle Proteins; 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins; 9006-99-9 / Bence Jones Protein
  •  go-up   go-down


22. Bampoe J, Nag S, Leung P, Laperriere N, Bernstein M: Brain necrosis after permanent low-activity iodine-125 implants: case report and review of toxicity from focal radiation. Brain Tumor Pathol; 2000;17(3):139-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focal irradiation has emerged as a useful modality in the management of malignant brain tumors.
  • We report on the radiation dose distribution in the cerebellum of a patient who developed imaging and autopsy diagnosis of radiation necrosis after permanent iodine-125 implants for a solitary osseous plasmacytoma of her left occipital condyle.
  • A cytological diagnosis of solitary osseous plasmacytoma was made by transpharyngeal needle biopsy.
  • After an initial course of external beam radiation, the patient required further treatment with systemic chemotherapy 21 months later for clinical and radiographic progression of her disease.
  • She ultimately required subtotal surgical resection of an anaplastic plasmacytoma with intracranial extension.
  • Progressive systemic myeloma led to her death 11 years after presentation and 9 years after seed implantation.
  • [MeSH-minor] Algorithms. Cranial Nerves / pathology. Drug Implants. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Necrosis. Plasmacytoma / pathology. Plasmacytoma / radiotherapy. Skull Base Neoplasms / pathology. Skull Base Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11310921.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Iodine Radioisotopes
  •  go-up   go-down






Advertisement